May 19, 2023 Meeting of the Gastrointestinal Drugs Advisory Committee (GIDAC)

The committee will discuss new drug application (NDA) 212833, for obeticholic acid (OCA) 25mg oral tablets, submitted by Intercept Pharmaceuticals, Inc., for the treatment of pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH).